Business
Bioventus Reports First Quarter Financial Results
Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0%First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year periodNon-GAAP earnings* of $0.08 per share increased 33%Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025 DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financ
About this update from Bioventus Inc.
[{"type":"image","alt":"Bioventus, Inc.","displaySize":"","headline":null,"caption":"Bioventus, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/17b9c15cccb55f628dbafce6298a0302"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qQ49MJubWbfvVwM2vqI94Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/17b9c15cccb55f628dbafce6298a0302","width":300,"height":55}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Q1 reported revenue of $123.9 million declined 4.3%; Organic* revenue advanced 5.0%","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"First quarter net loss was $0.04 per share compared to a loss of $0.08 in the prior-year period","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-GAAP earnings* of $0.08 per share increased 33%","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"Company reiterated revenue, Adjusted EBITDA* and Non-GAAP EPS* guidance for full year 2025","length":90,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":319,"olType":false},{"type":"text","content":"DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 29, 2025.","length":259,"tagName":"p"},{"type":"text","content":"“Our Bioventus team delivered solid results to start the year and we are making substantial progress with executing our strategic plan,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “We remain well positioned to navigate the uncertain macro-environment while achieving above-market revenue growth through a multitude of diverse growth drivers, enhancing profitability and accelerating cash flow to create significant shareholder value.”","length":460,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Financial Results:","length":37,"tagName":"p"},{"type":"text","content":"For the first quarter, worldwide revenue of $123.9 million declined 4.3% from $129.5 million in the prior-year period. This performance reflects the impact from the prior-year divestiture of the Advanced Rehabilitation Business. Organic* revenue increased 5.0...